Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall

Published 21/11/2022, 13:18
Updated 21/11/2022, 13:18
© Reuters

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Monday, November 21st. Please refresh for updates.

  • Walt Disney (NYSE:DIS) stock soared 8.5% after the entertainment giant brought back Bob Iger as chief executive less than a year after he retired, in an attempt to boost investor confidence after a difficult year.

  • Digital World Acquisition (NASDAQ:DWAC) stock fell 3.2% after Elon Musk reinstated former President Donald Trump to his Twitter social media service, potentially undermining Trump's new platform Truth Social, which is owned by the special purpose acquisition vehicle.

  • Coinbase Global (NASDAQ:COIN) stock fell 6.2% with the cryptocurrency exchange struggling in the wake of rival FTX's collapse.
  • Carvana (NYSE:CVNA) stock fell 5.1% after the used car retailer announced late Friday another round of job cuts that will impact about 1,500 employees, or 8% of its workforce, as it attempts to cut costs.
  • Yum! Brands (NYSE:YUM) stock rose 0.3% after Bloomberg reported that Americana Restaurants, the Middle Eastern operator of Yum's KFC and Pizza Hut, is set to raise up to $1.8 billion from its initial public offering, at the top end of a marketed range.

  • Comerica (NYSE:CMA) stock rose 1.1% after Raymond James upgraded its stance on the financial services company to ‘outperform’ from market perform’, saying it can jump more than 20% from current levels.

  • Taiwan Semiconductor Manufacturing (NYSE:TSM) stock fell 1.7% after reports of a meeting between its CEO and Chinese President Xi Jinping in Thailand at the weekend created uncertainty about the company’s future.

  • Imago Biosciences (NASDAQ:IMGO) stock more than doubled after Merck & Company (NYSE:MRK) said it would acquire the cancer drug developer Imago BioSciences for a total equity value of $1.35B.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.